

Original Research Article

Development of a novel, rapid and validated HPTLC protocol for the quantitative estimation of marrubiin from the extract of *Marrubium vulgare* Linn.

ABSTRACT

Aim: To develop a novel, simple, precise and rapid HPTLC protocol for the analysis of marrubiin (a furan labdane diterpene) in herbal extracts and formulations.

Methodology: The marrubiin can be quantified by performing the HPTLC on silica gel F₂₅₄ plates using toluene: ethyl acetate: acetic acid (5:4:1) as mobile phase. The developed method was validated as per ICH guidelines.

Results: The protocol was found to be linear in the concentration range of 40-400ng/spot and simultaneous comparison of R_f (0.47 ± 0.05) and overlapping UV spectra of samples confirm the specificity of the method. The limit of detection (LOD) and limit of quantification (LOQ) of biomarker were found to be 15 and 40 ng by the selected method. The low value of % relative standard deviation (less than 2) in peak area on analyzing the sample on same and different days ensures the precision of the developed method. Further the recovery of more than 95% of the marrubiin affirms the accuracy of developed analytical method.


Conclusion: It can be concluded that the developed protocol could be beneficial for the qualitative and quantitative analysis of the marrubiin in herbal extracts and formulations.

Key words: *Analysis, chromatography, fingerprint, thin layer chromatography, Lamiaceae*

1. INTRODUCTION

The herbal extracts are the complex mixture of chemical constituents and separation of these entities is a quite challenging task. The quantitative and qualitative analysis of the different compounds in plant extracts with acute accuracy is need of the hour. The various chromatographic techniques such as high pressure liquid chromatography (HPLC), gas chromatography (GC), high performance thin layer chromatography (HPTLC) have been employed by large number of researchers for the analysis of herbal extracts ([1-4]. Of these the HPTLC was considered to be quite advantageous in terms of time saving, high output and cost effectiveness for the analysis of multi component samples. Moreover the analysis of

30 plant based mixtures with HPTLC having mass spectrum (MS) interface not only separate the various
31 constituents but the proportion and identity of biomarkers/compounds can also be recognized. [5-8].
32 Chemically the marrubiin (Figure 1) is a furan labdane diterpenoid, isolated from the various species of
33 *Marrubium* genus (family- Lamiaceae). Generally in India, the species *Marrubium vulgare* Linn is found at
34 an altitude of 5000 – 6000 ft in Kashmir region. This perennial herb is conventionally used as diuretic,
35 bitter tonic, expectorant, antipyretic and also useful in the treatment of bronchitis, joint pain and various
36 complications related to spleen, lever and uterus [9]. The pharmacological significance of the marrubiin
37 was approved by many scientists as it was found to possess the vasorelaxant, hypotensive,
38 cardioprotective, analgesic, antinociceptive, antidiabetic, gastroprotective, antioxidant and
39 antioedematogenic properties [10-18]. Due to its vast therapeutic potential, marrubiin could be included in
40 various herbal formulations. The multicomponent nature of polyherbal formulations necessitates the
41 requirement of a cost effective and specific analytical method to evaluate the marrubiin. The HPTLC has
42 its own inherent advantage as compared to gas chromatography (GC) and high performance liquid
43 chromatography (HPLC). Nevertheless the analytical strategies such as high pressure liquid
44 chromatography (HPLC) and gas chromatography (GC) can not be replaced but development of
45 optimized novel methods for phytopharmaceuticals by HPTLC were always proved to be quite useful.
46 Therefore an approach to develop a validated process for the qualitative and quantitative analysis of
47 marrubiin from plant extract by HPTLC has been planned and executed in the present research work.
48



49

Figure 1: Chemical structure of marrubiin

50 **2. METHODOLOGY**

51 **2.1 Plant sample and reagents**

52 The plant, *Marrubium vulgare* Linn was collected from the Pulwama district of Jammu and Kashmir state,
53 India in April 2013. The herb was identified by, Dr. Sunita Garg, taxonomist from National Institute of
54 Science Communication and Information Research, New Delhi, vide reference no
55 NISCAIR/RHMD/Consult/2013/2336-116 dated- 19-11-2013. A voucher specimen was kept in the
56 department for future reference. The **biomarker** marrubiin (HPLC grade) was procured from
57 Extrasynthese, France. The HPLC grade solvents were used in the study and obtained from
58 Spectrochem Pvt. Ltd., Mumbai, India.

59 **2.2 Preparation of test samples and reference solution**

60 The selected medicinal plant was dried and grounded using a household mixer grinder. The powder of
61 the drug (10 g) was sieved and extracted with ethanol (500 **mL**) in a soxhlet apparatus. After exhaustive
62 extraction the solution was filtered and concentrated through rotary evaporator. The extract was dried in
63 lyophilizer at **-40°C**, **powdered** and kept in dessicator before further use. For analysis of the extract by
64 HPTLC, the dried extract was dissolved in methanol to prepare a solution of 5 mg/**mL** concentration. The
65 solution (test sample) was filtered through a membrane filter (0.45 μ m) before applying on the stationary
66 phase (Silica gel plate). The solution of the standard compound was formed by dissolving the biomarker
67 (marrubiin) in methanol to get a concentration of 1 mg/**mL**. This solution was further diluted to reduce the
68 concentration upto 10 μ g/mL and termed as standard stock solution or reference solution.

69 **2.3 HPTLC analysis of different samples**

70 A HPTLC system (CAMAG, Muttenz, Switzerland) was used to analyze the test and reference samples
71 for the quantification of marrubiin. The precoated and preactivated plates of silica gel 60 F₂₅₄ (E. Merck)
72 supported on aluminum sheet were used as stationary phase. The various samples were applied using
73 CAMAG automatic sample applicator (Linomat V) with the help of micro syringe (100 μ L). The mobile
74 phase consisting of toluene, ethyl acetate and acetic acid in a ratio of 5:4:1 was used to develop the
75 chromatogram. The chromatogram was developed upto 80% height of plates by ascending technique in a
76 presaturated twin trough chamber with 20 **mL** of solvent system. The developed plates were dried at
77 room temperature and then heated at 110°C for 15 minutes on CAMAG TLC plate heater. The spots were

78 visualized in UV light of CAMAG TLC visualizer system at wavelength of 254 nm. The images of the
79 developed plates were captured using winCATS software. For the quantification of biomarker in the
80 samples, the plates were scanned in CAMAG TLC densitometric scanner at wavelength of 254 nm and
81 analyzed using winCATS 1.4.8 software. All the experiments were carried in laboratory conditions with
82 temperature of $26 \pm 2^{\circ}\text{C}$ and relative humidity was $50 \pm 5\%$. The resolved spots were used to determine
83 the retention factor (R_f).

84 **2.3.1 Development of calibration curve**

85 The marrubiin reference solution (10 $\mu\text{g}/\text{mL}$) was used to prepare the calibration curve which was used to
86 quantify the marrubiin in samples with unknown concentration. The ten different spots (4mm wide) of
87 reference solution with a volume of 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 μL were applied on the stationary
88 phase with the help of a micro syringe under the flow of N_2 gas. The spots were applied on the plate at a
89 distance of 10mm from bottom and side with a 4mm space between them. The each consecutive spot
90 was supposed to have 40, 80, 120, 160, 200, 240, 280, 320, 360, 400 ng of the marrubiin. The
91 chromatogram was developed by the method described in the previous section and R_f was calculated for
92 isolated spot (marrubiin). The plates were scanned and analyzed with winCATS computer software to
93 observe the area under curve (AUC) for each resolved spot. The mean peak area for each sample with
94 known concentration was used to plot the calibration curve. The equation of straight line was generated
95 by linear regression of the data and used to determine the concentration of biomarker (marrubiin) in test
96 sample.

97 **2.4 Validation of HPTLC protocol**

98 The HPTLC protocol for the quantification of marrubiin was validated as per the guidelines described by
99 International Conference on Harmonization (ICH) [19, 20].

100 **2.4.1 Linearity**

101 The linearity of the method was ascertained by plotting calibration graph between the various
102 concentrations of marker (40-400 ng/spot) compound to the corresponding area under curve (AUC). The
103 data was linearly analyzed to develop equation of straight line and coefficient of correlation (R^2) was
104 determined.

106 **2.4.2 Specificity and sensitivity**

107 The specificity of developed analytical procedure was confirmed by the simultaneously comparing the R_f
108 of marker compound in reference solution and test sample. Further it was ascertained by superimposing
109 the UV spectra of extract and standard solution. The limit of detection (LOD) and limit of quantification
110 (LOQ) are the measure of sensitivity for selected protocol. These were estimated by analyzing different
111 concentrations of marrubiin till the mean AUC was about three (for LOD) ten (for LOQ) times the standard
112 deviation (n=6).

113 **2.4.3 Precision**

114 The precision of the instrument and developed method was affirmed by repeated analysis of reference
115 sample (100 ng/spot) for six times. Further intraday and interday variability of procedure was determined
116 by analyzing the standard solution at three different concentration (60, 120, 180 ng/spot) in triplicate on
117 same day and different day. The results were communicated as % relative standard deviation (% RSD).

118 **2.4.5 Accuracy/Recovery**

119 The accuracy of the protocol was assessed by recovery after addition of 50,100,150% of marrubiin to a
120 previously analyzed standard solution (100ng/band). The experiment was conducted in triplicate at each
121 three level and percentage recovery and average recovery (%) was calculated.

122 **2.4.6 Robustness**

123 The robustness of the selected strategy was also evaluated by analyzing the chromatogram, for test
124 sample (300 ng/spot), developed by slightly fluctuating the development distance (8 ± 0.5 cm), volume of
125 mobile phase (20 ± 2 mL), composition of solvent system ($\pm 10\%$) and time taken for saturation (30 ± 5
126 min). The results were expressed as % RSD for each deliberate change in chromatographic conditions.

127 **2.4.7 Suitability of system**

128 To ensure the reproducibility of the results the suitability of the system was assured by performing the
129 HPTLC profile of the biomarker at concentration of 200 ng/spot (n=6). The chromatogram was developed
130 with selected mobile phase and plates were scanned to note the AUC and R_f for each concentration of
131 marrubiin. The standard deviation (SD), % RSD, and mean peak area was observed and reported.

132


133

134 **2.4.8 Quantification of marrubiin in herbal extract**

135 The *Marrubium vulgare* Linn extract was dissolved in ethanol to get a concentration of 5 mg/mL and
136 subjected to HPTLC evaluation for the quantification of marrubiin by developed method (n=3).


137 **3. Results and Discussion**

138 The development of chromatographic fingerprint for the selected extract could convey the necessary
139 information to determine the proportion of dynamic constituents in a quite short span. The fingerprint
140 patterns also guarantee about the consistency of extract and make it assessable to confirm the quantity
141 of all discernible analytes [21]. The various solvents in different proportion were tried to analyze the
142 marrubiin in the extract and reference solution. After conducting the large number of experiments the
143 mobile phase consisting of toluene: ethyl acetate: glacial acetic acid (5:4:1) was selected. The different
144 samples were applied with a band width of 4mm on the plates to enhance the response of detector and
145 accuracy in scanning results was also improved. The simultaneous development of chromatogram for
146 standard and test sample confirmed that the marrubiin was well resolved at R_f of about 0.47 (Figure 2).
147 The HPTLC chromatogram developed with the selected mobile phase for standard and extract solution
148 confirmed that the marrubiin was present in the test sample (Figure 3).




149

150 **Figure 2: Photomicrograph of TLC plate with the spot of marrubiin in (i) Standard sample (ii) & (iii) test sample**



(a)



(b)

151

152

Figure 3: Area under curve (AUC) for marrubiin in (i) standard sample (ii) test sample

153 **3.1 Validation of HPTLC protocol**

154 **3.1.1 Linearity**

155 The calibration curve plotted in the selected range and was found to be linear (Figure 4). The linearity
 156 equation generated by regression analysis of data was $Y = 8.705 X + 445.98$ where Y is the mean peak
 157 area (AUC) and X represents the concentration of particular sample. The 3 D diagram representing the
 158 AUC for the different concentration of marker compound in reference and test samples was depicted in
 159 figure 5. A high R^2 value (0.996) signifies how close the data fits the regression line.




Figure 4: Calibration curve of marrubiin

160
161





Figure 5: 3D diagram with AUC for various standard samples and test samples

162
163

164 3.1.2 Specificity and sensitivity

165 The specificity of the developed method was confirmed by absence of interference in detection of
166 marrubiin from test samples with $R_f = 0.47 \pm 0.05$. Moreover the UV spectra of two samples was
167 overlapped in the region of 254 nm which further assured the specificity of the method for determination
168 of marrubiin in extract (Figure 6). The method sensitivity was evaluated by analyzing the different
169 concentration of marker compound (5 – 50 ng/spot). The observed LOD and LOQ for marrubiin in the
170 selected protocol was 15 and 40 ng respectively (Table 1).



171 **Figure 6: UV overlay spectra confirming presence of marrubiin in extract**

172
173

Table 1: Summary of validation parameters for analysis of marrubiin by HPTLC

Validation Parameter	Value
Linear regression equation	$Y=8.705 X + 445.98$
Regression coefficient (R^2)	0.996
Linearity range	40-400 ng
Retention factor (R_f)	0.47 ± 0.05
Instrument precision at 100 ng/band; n=6 (%RSD)	0.70
Limit of detection (LOD)	15 ng
Limit of quantification (LOQ)	40 ng
Repeatability at 200 ng/band; n=6 (%RSD)	0.27
Marrubiin in test sample at 5 mg/mL; n=3 (%)	0.69 ± 0.04
Robustness	Robust
Specificity	Specific

174 **3.1.3 Precision**

175 The random investigation of the precision of instrument and protocol on same day (intraday) and different
176 day (interday) established the validity of analytical procedure. The low value of % relative standard
177 deviation (<2%) for different parameters confirms that the developed method was precise and
178 reproducible (Table 2).

179
180
181
182
183

184

Table 2: Validation of precision parameter for marrubiin by HPTLC

Marker Concentration (ng/band)	Inter-day precision*		Intra-day precision*	
	Mean peak area \pm SD	%RSD	Mean peak area \pm SD	%RSD
60	1006.6 \pm 6.18	0.61	1009.3 \pm 17.55	0.41
120	1475.6 \pm 3.68	0.24	1471.3 \pm 11.57	0.78
180	1968.3 \pm 30.64	1.51	1971.0 \pm 7.3	0.37

185 * n = 3 for each concentration; values are expressed as mean \pm Standard deviation

186

3.1.4 Accuracy/Recovery188 The recovery of more than 95% of marrubiin in preanalyzed samples after spiking with known
189 concentration of standard sample confirmed the accuracy of the method. The recovery results are
190 depicted in table 3.

191

Table 3: Recovery studies to validate the accuracy of HPTLC protocol for marrubiin

Amount of marker in Preanalyzed sample (ng/spot)	Amount of marker spiked (%)	Mean peak area \pm SD (Preanalyzed sample + standard)	Total area obtained \pm SD	Recovery (%) \pm SD	% RSD
100	50	1923.26 \pm 2.23	1901.5 \pm 3.22	98.8 \pm 0.95	0.96
	100	2498.9 \pm 3.81	2425.5 \pm 12.27	97.06 \pm 0.54	0.56
	150	3151.4 \pm 7.51	3071.7 \pm 22.33	97.45 \pm 0.61	0.63
Average Recovery				97.77 \pm 1.25	

193 Analysis in triplicate at each level (n=3); values are expressed as mean \pm Standard deviation
194**3.1.5 Robustness**196 The slight deviation in the selected parameters did not represent any huge fluctuation in %RSD (less than
197 2%) which clearly justify the robustness of the derived protocol (Table 4).

198

199

200

201 **Table 4: Robustness of developed HPTLC method for marrubiin analysis**

Test sample (ng/spot)	Chromatogram development conditions	Mean peak area \pm SD	RSD (%)
300	Development distance (8 ± 0.5 cm), Volume of mobile phase (20 ± 2 mL) Composition of solvent system ($\pm 10\%$) Time taken for saturation (30 ± 5 min)	2996.63 ± 24.12 2963.13 ± 36.46 3032.9 ± 51.79 3021.86 ± 8.36	0.80 1.23 1.71 0.27

202 n=3 for each conditions; values are expressed as mean \pm Standard deviation

203

204 **3.1.6 System suitability**

205 The mean peak area for selected concentration of standard sample (200 ng/spot) was found to be 2084.1

206 \pm 5.75 with %RSD of 0.27. Moreover the R_f for the marrubiin was confirmed at 0.47 ± 0.05 . The small

207 value of %RSD confirms the suitability for the analysis of marrubiin in extract.

208 **3.1.7 Quantification of marrubiin:**

209 The prepared extract of *Marrubium vulgare* Linn was analyzed by developed method in triplicate and the

210 percentage of marrubiin was quantified to be 0.69 ± 0.04 .

211

212 **4. CONCLUSION**

213 The marrubiin is considered to be the chemotaxonomic marker for the plants related to *Marrubium genus*

214 of Lamiaceae family. Hence the developed and validated chromatographic fingerprint pattern for

215 marrubiin by HPTLC could be beneficial for the evaluation of particular plant species. Moreover the

216 developed pattern clearly speaks about the various chemical entities of the extract and could be

217 employed for the qualitative and quantitative assessment of marrubiin in the herbal formulations.

218 **CONSENT**

219 It is not applicable

220 **ETHICAL APPROVAL**

221 It is not applicable

222 **REFERENCES**

223

224 1. Misra H, Mehta D, Mehta BK, Jain DC. Extraction of Artemisinin, an active antimalarial

225 phytopharmaceuticals from dried leaves of *Artemisia annua* L. using microwaves and a validated

226 HPTLC-Visible method for its quantitative determination. *Chromatography Research*

227 *International*. 2014; 1-11.

228

229 2. Ramya V, Dhayalan DV, Umamaheswari S. *In vitro* studies on antibacterial activity separation of
230 active compounds of selected flower extracts by HPTLC. *J. Chem. Pharm. Res.* 2010; 2 (6): 86-
231 91.

232 3. Chen SB, Liu HP, Tian RT, Yang DJ, Chen SL, Xu H, Chan ASC, Xie PS. High performance thin
233 layer chromatographic fingerprints of isoflavonoids for distinguishing between *Radix puerariae*
234 Lobata and *Radix puerariae* Thomsonii, *J. Chromatogr. A.* 2006; 1121 (1): 114-119.

235 4. Lu HM, Liang YZ, Chen S, Lu H, Liang Y, Chen S. Identification and quality assessment of
236 *Houttuynia cordata* injection using GC-MS fingerprint: A standardization approach. *J. Ethnopharmacol.* 2006; 105 (3): 436-440.

237 5. Shewiyo DH, Kaaleb E, Rishabh PG, Dejaegher B, Verbeke JS, Heydene YV. HPTLC methods
238 to assay active ingredients in pharmaceutical formulations: A review of method development and
239 validation steps. *J. Pharm. Biomedical anal.* 2012; 66: 11-23.

240 6. Sethi PD. Quantitative analysis of pharmaceutical formulations, High Performance thin layer
241 chromatography. 1st edition. New Delhi: CBS Publishers and Distributors. 1996; 1-30.

242 7. Li K, Wang S. Fingerprint chromatogram analysis of extracts from the leaves of *Tripterygium*
243 *wilfordii* Hook. F. by high performance liquid chromatography. *J. Sep. Sci.* 2005; 28 (7): 653-657.
244 .

245 8. Xie P, Chen S, Liang Y, Wang X, Tian R, Upton R. Chromatographic fingerprint analysis- a
246 rational approach for quality assessment of traditional Chinese herbal medicine. *J. Chromatogr.*
247 *A.* 2006; 1112 (1): 171-180.

248 9. Kirtikar KR, Basu BD. Indian medicinal plants.2nd edition. Dehradun: International Book
249 Distributors. 1996; 3: 2007-2009.

250 10. El Bardai S, Morel N, Wibo M, Fabre N, Llabres G, Lyoussi B, Quetin-Leclercq J. The
251 vasorelaxant activity of marrubenol and marrubiin from *Marrubium vulgare*. *Planta Med.* 2003; 69:
252 75-77.

253 11. El Bardai S, Lyoussi B, Wibo M, Morel N. Pharmacological evidence of hypotensive activity of
254 *Marrubium vulgare* and *Foeniculum vulgare* in spontaneously hypertensive rat. *Clin. Exp.*
255 *Hypertens.* 2001; 23: 329-343.

256 12. Mnonopi N, Levendal RA, Davies-Coleman RT, Frost CL. The cardioprotective effects of
257 marrubiin, a diterpenoid found in *Leonotis leonurus* extracts. *J. Ethnopharmacol.* 2011; 138: 67-
258 75.

259 13. Meyre-Silva C, Yunes RA, Schlemper V, Campos-Buzzi F, Cechinel-Filho V. Analgesic potential
260 of marrubiin derivatives, a bioactive diterpene present in *Marrubium vulgare* (Lamiaceae).
261 *Farmaco.* 2005; 60: 321-326.

262 14. De Jesus RAP, Cechinel-Filho V, Oliveira AE, Schlemper V. Analysis of the antinociceptive
263 properties of marrubiin isolated from *Marrubium vulgare*. *Phytomedicine.* 2000; 7: 111-115.

264 15. Mnonopi N, Levendal RA, Mzilikezi N, Frost CL. Marrubiin, a constituent of *Leonotis leonurus*,
265 alleviates diabetic symptoms. *Phytomedicine.* 2012; 19: 488-493.

266 16. Paula de Olivera A, Santin JR, Lemos M, Klein LCJ, Couto AG, Bittencourt CMS, Cechinel F,
267 Valdir FA. Gastroprotective activity of methanol extract and marrubiin obtained from leaves of
268 *Marrubium vulgare* L. (Lamiaceae). *J. Pharm. Pharmacol.* 2011; 63: 1230-1237.

285
286 17. Zaabat N, Hay AE, Michalet S, Darbour N, Bayet C, Skandrani I, Chekir-Ghedira L, Akkal S,
287 Dijoux-Franca MG. Antioxidant and antigenotoxic properties of compounds isolated from
288 *Marrubium deserti* de Noe. *J. Food Chem. Toxicol.* 2011; 49: 3328-3335.
289
290 18. Stulzer HK, Tagliari MP, Zampirolo JA, Cechinel-Filho V, Schlemper V. Antioedemagenic effect
291 of marrubiin obtained from *Marrubium vulgare*. *J. Ethnopharmacol.* 2006; 108: 379-384.
292
293 19. ICH Harmonised Tripartite Guidelines, Validation of analytical procedures: Text and methodology,
294 Q2(R1), Geneva, 2005; 6-13.
295
296 20. Patel R, Patel M, Dubey N, Dubey N, Patel B, HPTLC method development and validation:
297 Strategy to minimize methodological failures. *J. Food Drug Anal.* 2012; 20 (4): 794-804.
298
299 21. Gomathi D, Ravikumar G, Kalaiselvi M, Vidya B, Uma C. HPTLC fingerprint analysis of *Evolvulus*
300 *alsinoides* (L.). *J. Acute Med.* 2012; 2(3): 77-82.
301
302